Ajinomoto Bio-Pharma Services Awarded CDMO Leadership Awards

• Ajinomoto Bio-Pharma Services recognized in "Global Biologics" category
• Forge Biologics, a member of Ajinomoto-Bio-Pharma Services, recognized in "Global Cell & Gene Therapy" category

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, and Forge Biologics ("Forge"), a member of Aji Bio-Pharma Services and leading manufacturer of genetic medicines, received CDMO Leadership Awards in the Global Biologics and Cell & Gene Therapy categories, respectively.

The CDMO Leadership Awards are presented by Life Science Leader and Outsourced Pharma. Respondents evaluated 210 contract manufacturers across various performance metrics. Respondents only evaluate companies with which they have worked on an outsourced project within the past 24 months. This level of qualification ensures that survey responses are based on actual involvement with contract manufacturers and clear experiential data to recognize top outsourcing partners.

"We are honored to be recognized as a global CDMO leader. This achievement is especially meaningful because it reflects feedback from our clients—those who trust us to help bring their transformative treatments to patients. It is particularly exciting to see Forge Biologics, the newest member of the Aji Bio-Pharma group, recognized for its leadership in cell and gene therapy as a CDMO supporting developers in advancing treatments for genetic diseases. Together with our partners, we remain dedicated to providing exceptional service for our clients and the patients they serve," said Yasuyuki Otake, Corporate Executive, Ajinomoto Co., and General Manager, Bio-Pharma Services Department.

About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates, and gene therapies. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing, and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet its client's needs. Learn more: www.AjiBio-Pharma.com

Media Inquiries
Betty Wu
Vice President of Client Experience
[email protected] 

SOURCE Ajinomoto Bio-Pharma Services